Two analysts polled by Capital IQ expected $0.47.
Net sales for the quarter ended Jan. 30 were $270.8 million, up from $256 million a year ago. Three analysts surveyed by Capital IQ expected $278.7 million.
For fiscal 2022, the company expects EPS to be in a range of $0.93 to $1.02 and net sales of $730 million to $755 million. Analysts polled by Capital IQ are expecting EPS of $0.85 on revenue of $706.5 million.
Insider Sell: Block |
Insider Sell: Berkshire Hathaway |
Insider Sell: Trupanion |
Insider Buy: Ikena Oncology |
Insider Sell: Apellis Pharmaceuticals |